Tempest Therapeutics Company Insiders
| TPST Stock | USD 6.30 0.36 5.41% |
Tempest Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Tempest Therapeutics suggests that vertually all insiders are panicking. Tempest Therapeutics employs about 24 people. The company is managed by 10 executives with a total tenure of roughly 56 years, averaging almost 5.0 years of service per executive, having 2.4 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-08-12 | Versant Venture Capital Vi, L. | Disposed 29846 @ 14.3 | View | ||
| 2024-08-08 | Versant Venture Capital Vi, L. | Disposed 30769 @ 17.55 | View |
Monitoring Tempest Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Tempest Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Tempest Therapeutics' future performance. Based on our forecasts, it is anticipated that Tempest will maintain a workforce of slightly above 20 employees by August 2025.Tempest Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7347) % which means that it has lost $0.7347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8207) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.06 in 2025. Return On Capital Employed is likely to drop to -1.62 in 2025. At this time, Tempest Therapeutics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 12.3 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2025.Common Stock Shares Outstanding is likely to gain to about 29.3 M in 2025, whereas Net Loss is likely to drop (26.7 M) in 2025.
Tempest Therapeutics Workforce Comparison
Tempest Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 582. Tempest Therapeutics holds roughly 24.0 in number of employees claiming about 4% of equities under Health Care industry.
Tempest Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tempest Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 1.0 | 2 | 2 | 39,672 | 787,999 |
| 2022-06-01 | 14.0 | 14 | 1 | 2,607,706 | 0.00 |
| 2021-06-01 | 24.0 | 24 | 1 | 6,820,074 | 0.00 |
| 2021-03-01 | 0.3333 | 3 | 9 | 534,000 | 105,340 |
| 2019-09-01 | 0.6667 | 2 | 3 | 140,000 | 107,569 |
| 2018-12-01 | 23.0 | 23 | 1 | 864,293 | 0.00 |
| 2017-09-01 | 3.0 | 3 | 1 | 19,233 | 1,783,106 |
| 2017-06-01 | 2.0 | 12 | 6 | 301,365 | 47,500 |
| 2016-12-01 | 4.0 | 8 | 2 | 1,025,863 | 800,361 |
| 2016-09-01 | 6.0 | 6 | 1 | 255,384 | 0.00 |
| 2015-12-01 | 3.0 | 12 | 4 | 294,471 | 204,176 |
| 2015-09-01 | 4.5 | 9 | 2 | 16,112 | 2,015 |
| 2015-06-01 | 13.0 | 26 | 2 | 325,465 | 176,737 |
| 2015-03-01 | 2.0 | 8 | 4 | 307,888 | 1,317,613 |
| 2014-12-01 | 1.3333 | 8 | 6 | 993,294 | 149,228 |
| 2014-09-01 | 5.5 | 11 | 2 | 281,647 | 1,005,201 |
| 2014-06-01 | 22.0 | 22 | 1 | 570,846 | 5,938 |
| 2014-03-01 | 3.0 | 6 | 2 | 412,200 | 5,081 |
| 2013-12-01 | 2.5 | 5 | 2 | 185,230 | 11,813 |
| 2013-09-01 | 6.0 | 6 | 1 | 329,200 | 5,224 |
| 2013-06-01 | 11.0 | 11 | 1 | 242,828 | 5,188 |
| 2013-03-01 | 5.0 | 5 | 1 | 858,097 | 5,863 |
| 2012-12-01 | 4.0 | 4 | 1 | 532,616 | 0.00 |
| 2012-09-01 | 1.1429 | 16 | 14 | 17,791,456 | 24,295,028 |
Tempest Therapeutics Notable Stakeholders
A Tempest Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tempest Therapeutics often face trade-offs trying to please all of them. Tempest Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tempest Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| LLM JD | President CEO | Profile | |
| Nicholas Maestas | VP Secretary | Profile | |
| Justin CPA | Treasurer Controller | Profile | |
| Dr Dubensky | Pres Director | Profile | |
| Justin Trojanowski | Treasurer Controller | Profile | |
| RAC Sakai | Head Quality | Profile | |
| Samuel MD | Executive Officer | Profile | |
| Petpiboon Prasit | Acting Director | Profile | |
| Anne Moon | Project Leadership | Profile | |
| Lindsay Young | Head Resources | Profile |
About Tempest Therapeutics Management Performance
The success or failure of an entity such as Tempest Therapeutics often depends on how effective the management is. Tempest Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tempest management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tempest management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.01) | (1.06) | |
| Return On Capital Employed | (1.54) | (1.62) | |
| Return On Assets | (1.01) | (1.06) | |
| Return On Equity | (2.19) | (2.30) |
Please note, the imprecision that can be found in Tempest Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tempest Therapeutics. Check Tempest Therapeutics' Beneish M Score to see the likelihood of Tempest Therapeutics' management manipulating its earnings.
Tempest Therapeutics Workforce Analysis
Traditionally, organizations such as Tempest Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tempest Therapeutics within its industry.Tempest Therapeutics Manpower Efficiency
Return on Tempest Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 4.2M | |
| Working Capital Per Employee | 718.9K | |
| Working Capital Per Executive | 1.7M |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.